Other

Katholieke Universiteit Leuven

Cobiores Nv

Stefan Janssens

Kenneth D Bloch

Paul N Holvoet

D&eacute;sir&eacute; Jos&eacute; Collen

Olivier Henry Varenne

Peter Sinnaeve

D&eacute;sir&eacute; Collen

Ming Wu

The present invention relates to diagnosis and/or prognosis of cardiovascular disease and cardiovascular events. A prognostic risk score in relation to the cardiovascular events, more particular after intervention, can be determined by counting the number of deregulated genes (or derived proteins) in their isolated monocytes. Deregulation means low expression of COX1 and/or COX4I1, and/or TFAM, and/or RUNX2.

Oxidative stress and cardiovascular disease events

This invention relates to a gene therapy method for inducing pulmonary vasodilation. More specifically, this invention involves introducing the nitric oxide synthase gene into lungs resulting in pulmonary vasodilation. This results in a hypotensive effect in the pulmonary circulation which does not significantly affect systemic blood pressure or cardiac index. This method is useful to treat primary pulmonary hypertension or pulmonary hypertension secondary to various disease states.

Method of inducing vasodilation and treating pulmonary hypertension using adenoviral-mediated transfer of the nitric oxide synthase gene

A catheter containing an inflatable balloon, which is at its periphery provided with hollow extensions that communicate between the outside of the balloon and the lumen of the catheter for use in the gene therapeutic treatment of local disorders by transfer of a desired gene to a target cell or tissue being part of or being located in the vicinity of a blood vessel. The catheter is preferably the Infiltrator&reg; catheter.

Gene therapeutic treatment of blood vessel associated disorders

Growing community of inventors

Heverlee, Belgium

Stefan Janssens